MERTK Activation Drives Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer

Treatment with MRX-2843, a first-in-class MERTK kinase inhibitor, re-sensitized GAS6-treated NSCLC cells to osimertinib.
[Journal of Clinical Investigation]
AbstractGraphical Abstract
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News